Scancell realisation – 5.5x money
Scancell develops DNA-based vaccines for cancer therapy, and potentially other indications. We invested in the company in three separate funding rounds, in 2008, 2010 and 2011. We sold our holding in the latter half of 2015, realising just over 5.5x cost, equating to an IRR over the life of the investment of 37% pre-EIS benefits, or 44% including them.